However, DCs comprise only 1–2% of peripheral blood mononuclear cells and isolating high numbers ex vivo is a challenge requiring the use of FMS-like tyrosine kinase 3 ligand (Flt3L)-producing tumor models or recombinant Flt3L and/or granulocyte-macrophage colony-stimulating factor cytokines to expand the available DC pool in vivo [1,2]. Here, FLT3LG is linked to neoplasm.